We are a bioinformatics research group in the Department of Biomedical Informatics at Harvard Medical School. We are part of the Ludwig Center at HarvardDivision of Genetics at Brigham and Women's Hospital and Harvard-MIT Division of Health, Science, & Technology

Our main aim is to understand the genetic and epigenetic mechanisms that underlie disease processes through computational and statistical analysis of genomic data. We are particularly interested in mutational processes in normal and cancer cells and their impact in gene regulation. 

Collaborative science

We have the privilege of collaborating with a number of superb experimental laboratories at Harvard Medical School and its affiliated hospitals, as well as around the world. Our recent and current collaborators include Connie Cepko, George Daley, Steve Elledge, Konrad Hochedlinger, Mark Johnson, Mitzi Kuroda, Jordan Kreidberg, Bob Kingston, William Pu, Charlie Roberts, Chris Walsh, Fred Winston.

Here are some consortium projects in which we are involved:

  • 4D Nucleome - What are the principles underlying three-dimensional organization of the human genome? What is the role of the nuclear architecture in gene regulation? As the Data Coordination and Analysis Center for this major NIH initiative, we will collect, process, and display all data generated in the consortium and to perform integrative analysis. Main collaborators: Peter Kharchenko (HMS), Leonid Mirny (MIT), Nils Gehlenborg (HMS), Hanspeter Pfister (Harvard) and Ting Wang (WashU).
  • Brain Somatic Mosaicism Network - The aim of this network is to characterize the spectrum of somatic variation in human brain samples and its role in psychiatric disorders. We are studying somatic mosaicism in autism with Chris Walsh (Boston Children's) and schizophrenia with Andy Chess (Mt. Sinai).
  • Ludwig Center - This center brings together investigators from across Harvard to develop strategies to overcome the problem of therapy resistence in cancer.
  • International Cancer Genome Consortium - This is an effort by the international cancer genomics community to jointly analyze ~2,500 cancer genomes.

Our research is supported by: 

Park Lab Research Support


  • ParkLabGenomics
    ParkLabGenomics Here is the flowchart of the algorithm. It is intuitively clear that algorithms that incorporate more features at the read-level should perform better (as some recent algorithms do); the hard part was coming up with enough true positives to train the classifier. t.co/cCbl8lWV11
  • ParkLabGenomics
    ParkLabGenomics Yanmei's paper is out today. MosaicForecast uses 30+ read-level features (+ML) to identify mosaic mutations in normal cells, where the variant allele fraction is << what you typically see in cancer cells. A key innovation is to use haplotype phasing to generate a training set. t.co/FDMnizwF71
  • ParkLabGenomics
    ParkLabGenomics Multiple postdoc positions available in the lab! See t.co/cSvPfNselu A great deal of independence (if desired), a lot of exciting projects in cancer genomics/neurogenetics--single cell WGS, mutational signatures, CRUK Grand Challenge, antisense oligo therapeutics, etc
  • ParkLabGenomics
    ParkLabGenomics Jake presents his work from his recent Cell paper at this lung cancer meeting and wins the Grand Prize (10K)! t.co/d0dFfcKtdn
  • 4dn_dcic
    4dn_dcic We're inspired by all the great talks at the #4DNucleome annual meeting this year & excited for phase 2! Reach out to us at support@4dnucleome.org to submit your recent data!

Latest News

Happy Holidays!

December 16, 2019

Our lab has grown quite big this past year! We had a wonderful time gathering with friends, families, and old faces. We hope everyone has a wonderful holiday season and a happy new year!



Read more about Happy Holidays!
Cancer Research UK

Cancer Research UK's Grand Challenge

March 11, 2019

The Park lab has been funded by Cancer Research UK’s Grand Challenge, which provides £20M over 5 years to a team to work on toughest problems in cancer research. Our team, led by our long-time collaborator Steve Elledge, includes a number of investigators from US/UK/Netherlands. We will attempt to understand why there is such tissue-specificity in cancer drivers--i.e., why one oncogene causes cancer in one tissue but does not in another.


Read more about Cancer Research UK's Grand Challenge